Should I take hormone therapy to prevent disease, or only to treat symptoms?

Both are talking about healthy women under 60 or within ten years of their final period, so for once they really are describing the same women. What differs is what they want the therapy to do, not who takes it. Haver's case is strongest for bone, where the guideline supports her, and weakest for cardiovascular disease and mortality, where it does not. Gunter's case is a refusal to act on the weakest limb, not a denial of the strongest one: she names elevated fracture risk as an indication, so the two agree about bone.

Neither is talking about women more than ten years out or over 60, where both would apply more caution, and neither is talking about vaginal oestrogen, which is a different therapy that Gunter is at pains to separate out.

More than either audience assumes. Both hold that the Women's Health Initiative was over-read into a blanket prohibition and that a generation of women was under-treated as a result. Both recommend hormone therapy for vasomotor symptoms and for elevated fracture risk. Both say it should not be started to prevent dementia in average-risk women, which Haver states explicitly in hav-ht-not-dementia.

Both treat genitourinary syndrome of menopause as under-recognised and treatable. Both hold that resistance training, not a supplement, is the intervention that protects muscle and bone. The live disagreement is narrow and it is about one thing: whether the evidence for cardiovascular, metabolic and mortality benefit is strong enough to make prevention a reason to start.

A randomised trial of hormone therapy initiated inside the ten-year window with cardiovascular events as a primary endpoint, which does not currently exist and is the whole reason the disagreement is live.

Short of that, a change in The Menopause Society's position on primary prevention would move both sides at once, because both cite it. Haver's position would also move on a strong null from a large early-initiation cohort; Gunter's position is already the conservative reading, so it moves only on positive trial data.